Description
GenomeMe is a manufacturer specializing in molecular pathology antibodies for diagnostics. With the availability and competitiveness of quality and price, we aim to expand our business and market in European healthcare market.
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02019-07-10$20,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2019-07-10(start date) | $20,000 | — | GenomeMe is a manufacturer specializing in molecular pathology antibodies for diagnostics. With the availabili… |
Related records · 7
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 801765397)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2023-2024-Q2-1008278 | National Research Council Canada | Conseil national de recherches Canada · CanExport SME | $20,000 | FY2024 |
| 172-2018-2019-Q3-915829 | National Research Council Canada | Conseil national de recherches Canada · CanExport | $25,750 | FY2019 |
Other recipients funded under "CanExport" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2026-2027-Q1-1044054 | Response Biomedical Corp. | FY2027 | $19,120 | FY2027 |
| 172-2026-2027-Q1-1043922 | Optii Corporation | FY2027 | $10,433 | FY2027 |
| 172-2026-2027-Q1-1044221 | M2M TECH INC. | FY2027 | $7,834 | FY2027 |
| 172-2026-2027-Q1-1044158 | Titan Clean Energy Projects Corporation | FY2027 | $3,600 | FY2027 |
| 172-2026-2027-Q1-1044096 | SPARC GLOBAL SOLUTIONS INC. | FY2027 | $8,549 | FY2027 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2019-2020-Q2-931628 · retrieved 2026-11-14.